Dr. Velleca is the CEO of G1 Therapeutics. Previously, he was instrumental in founding, building, and leading CGI Pharmaceuticals up through its acquisition by Gilead Sciences in 2010. Dr. Velleca served as a senior advisor to Gilead, helping build its oncology pipeline through prioritization of internal programs, academic partnerships, in-licensing, technology deals and acquisitions. He most recently served as executive vice president at The Leukemia & Lymphoma Society. Earlier in his career, Dr. Velleca was an attending physician at Yale New Haven Hospital and on the faculty of Yale University School of Medicine.
Dr. Velleca earned a B.S. cum laude from Yale University and an M.D. and Ph.D. from Washington University in St. Louis. He has served on the board of directors and scientific advisory boards of several biotechnology companies and his opinions on healthcare have been published in The New England Journal of Medicine, The New York Times, and The Los Angeles Times.